Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• Pathological changes of a malignant liver tumor after systemic therapies
  di: Shinya Kuwabara, et al.
  Pubblicazione: (2025)
• Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease
  di: Kazuhiro Nouso, et al.
  Pubblicazione: (2024)
• Hepatic Mac2‐BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction‐associated steatotic liver disease
  di: Haruki Uojima, et al.
  Pubblicazione: (2024)
• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease
  di: Qian‐Qian Wang, et al.
  Pubblicazione: (2025)